PubMed=8168083
Thalmann G.N., Anezinis P.E., Chang S.-M., Zhau H.E., Kim E.E., Hopwood V.L., Pathak S., von Eschenbach A.C., Chung L.W.K.
Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer.
Cancer Res. 54:2577-2581(1994)
PubMed=15162376; DOI=10.1002/pros.20031
Liu A.Y., Brubaker K.D., Goo Y.A., Quinn J.E., Kral S., Sorensen C.M., Vessella R.L., Belldegrun A.S., Hood L.E.
Lineage relationship between LNCaP and LNCaP-derived prostate cancer cell lines.
Prostate 60:98-108(2004)
PubMed=24587179; DOI=10.1371/journal.pone.0090002
Spans L., Helsen C., Clinckemalie L., Van den Broeck T., Prekovic S., Joniau S., Lerut E., Claessens F.
Comparative genomic and transcriptomic analyses of LNCaP and C4-2B prostate cancer cell lines.
PLoS ONE 9:E90002-E90002(2014)
PubMed=33298586; DOI=10.1158/1535-7163.MCT-20-0244
Kohrt S.E., Awadallah W.N., Phillips R.A. III, Case T.C., Jin R.-J., Nanda J.S., Yu X.-P., Clark P.E., Yi Y.-J., Matusik R.J., Anderson P.D., Grabowska M.M.
Identification of genes required for enzalutamide resistance in castration-resistant prostate cancer cells in vitro.
Mol. Cancer Ther. 20:398-409(2021)